Literature DB >> 26318520

Renal cancer.

Umberto Capitanio1, Francesco Montorsi2.   

Abstract

The diagnosis and management of renal cell carcinoma have changed remarkably rapidly. Although the incidence of renal cell carcinoma has been increasing, survival has improved substantially. As incidental diagnosis of small indolent cancers has become more frequent, active surveillance, robot-assisted nephron-sparing surgical techniques, and minimally invasive procedures, such as thermal ablation, have gained popularity. Despite progression in cancer control and survival, locally advanced disease and distant metastases are still diagnosed in a notable proportion of patients. An integrated management strategy that includes surgical debulking and systemic treatment with well established targeted biological drugs has improved the care of patients. Nevertheless, uncertainties, controversies, and research questions remain. Further advances are expected from translational and clinical studies.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26318520     DOI: 10.1016/S0140-6736(15)00046-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  265 in total

1.  Kidney cancer in Saudi Arabia. A 25-year analysis of epidemiology and risk factors in a tertiary center.

Authors:  Sultan S Alkhateeb; Ali S Alothman; Abdulmalik M Addar; Raed A Alqahtani; Tarek M Mansi; Emad M Masuadi
Journal:  Saudi Med J       Date:  2018-05       Impact factor: 1.484

2.  A TOP2A-derived cancer panel drives cancer progression in papillary renal cell carcinoma.

Authors:  Mushi Ye; Zhuobin He; Wei Dai; Zhuo Li; Xiaojun Chen; Jianjun Liu
Journal:  Oncol Lett       Date:  2018-07-19       Impact factor: 2.967

3.  Complete response after treatment with first-line targeted anti-vascular endothelial growth factor therapy in metastatic renal cancer: what next?

Authors:  Emanuele Zaffuto; Pierre I Karakiewicz; Umberto Capitanio
Journal:  Ann Transl Med       Date:  2016-08

Review 4.  Pneumodissection during Percutaneous Renal Ablation Resulting in Air Embolism: Percutaneous Management and a Review of the Literature.

Authors:  Kamil Arif; Andrew J Gunn
Journal:  Semin Intervent Radiol       Date:  2019-05-22       Impact factor: 1.513

5.  What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality?

Authors:  Meta H Diekstra; Xiaoyan Liu; Jesse J Swen; Henk-Jan Guchelaar
Journal:  Pharmacogenomics       Date:  2016-12-14       Impact factor: 2.533

Review 6.  Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience.

Authors:  Alessia Mennitto; Paolo Grassi; Raffaele Ratta; Elena Verzoni; Michele Prisciandaro; Giuseppe Procopio
Journal:  Ther Adv Urol       Date:  2016-07-07

Review 7.  Precision medicine from the renal cancer genome.

Authors:  Yasser Riazalhosseini; Mark Lathrop
Journal:  Nat Rev Nephrol       Date:  2016-10-03       Impact factor: 28.314

8.  Dynamic changes of different phenotypic and genetic circulating tumor cells as a biomarker for evaluating the prognosis of RCC.

Authors:  Zhen-Long Wang; Peng Zhang; He-Cheng Li; Xiao-Jie Yang; Ya-Ping Zhang; Zhao-Lun Li; Li Xue; Yu-Quan Xue; Hong-Liang Li; Qi Chen; Tie Chong
Journal:  Cancer Biol Ther       Date:  2018-10-25       Impact factor: 4.742

9.  High fidelity of driver chromosomal alterations among primary and metastatic renal cell carcinomas: implications for tumor clonal evolution and treatment.

Authors:  Eril J Kouba; John N Eble; Novae Simper; David J Grignon; Mingsheng Wang; Shaobo Zhang; Lisha Wang; Guido Martignoni; Sean R Williamson; Matteo Brunelli; Claudio Luchini; Anna Calió; Liang Cheng
Journal:  Mod Pathol       Date:  2016-07-29       Impact factor: 7.842

10.  Risk Based Surveillance after Surgical Treatment of Renal Cell Carcinoma.

Authors:  Paolo Capogrosso; Alessandro Larcher; Daniel D Sjoberg; Emily A Vertosick; Francesco Cianflone; Paolo Dell'Oglio; Cristina Carenzi; Andrea Salonia; Andrew J Vickers; Francesco Montorsi; Roberto Bertini; Umberto Capitanio
Journal:  J Urol       Date:  2018-01-31       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.